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Abstract
The negative impact of smoking in MS is well established, however, there is much less 
evidence as to whether smoking cessation is beneficial to progression in MS.
Adults with MS registered on the United Kingdom MS Register (2011-2020) formed this 
retrospective and prospective cohort study. Primary outcomes were changes in 3 patient 
reported outcomes (PROs): normalised MS Physical Impact Scale (MSIS-29-Phys), 
normalised MS Walking Scale (MSWS-12) and the Hospital Anxiety and Depression Scale 
(HADS-Anxiety and HADS-Depression). Time to event outcomes were clinically significant 
increases in the PROs.
7983 participants were included, 4130 (51.7%) of these had ever smoked; of whom 1315 
(16.5%) were current smokers and 2815/4130 (68.2%) were former smokers. For all PROs, 
current smokers at the time of completing their first questionnaire had higher PRO scores 
indicating higher disability compared to those who had never smoked (~10 points difference 
in MSIS-29-Phys and MSWS-12; 1.5-1.8 point for HADS-anxiety and HADS-depression). 
There was no improvement in PRO scores with increasing time since quitting in former 
smokers. 
923 participants formed the prospective parallel group, which demonstrated that MSIS-29-phy 
5.03, [3.71, 6.34], MSWS-12 5.28, [3.62, 6.94] and HADS-depression 0.71, [0.47, 0.96] 
worsened over a period of 4 years, whereas HADS-anxiety remained stable.  Smoking status 
was significant at year 4; current smokers had higher MSIS-29-Phys and HADS-Anxiety scores 
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(3.05 [0.22, 5.88], 1.14 [0.52,1.76]) while former smokers had a lower MSIS-29 score of -
2.91[-5.03, -0.79].
4642 participants comprised the time to event analysis. Still smoking was associated with a 
shorter time to worsening event in all PROs (MSIS-29-Phys: n=4436, p=0.0013; MSWS-12: 
n=3902, p=0.0061; HADS-anxiety: n=4511, p=0.0017; HADS-depression: n=4511, 
p<0.0001). Worsening in motor disability (MSIS-29-Phys and MSWS-12) was independent of 
baseline HADS-anxiety and HADS-depression scores. There was no statistically significant 
difference in the rate of worsening between never and former smokers.
When smokers quit, there is a slowing in the rate of motor disability deterioration so that it 
matches the rate of motor decline in those who have never smoked. This suggests that smoking 
cessation is beneficial for people with MS.
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Introduction
Retrospective studies have shown that people with MS (pwMS) who smoke have more 
significant motor symptoms 1, increased MRI activity and brain atrophy2,3 and more cognitive 
and psychological impairment 4,5. In relapsing MS smoking can lead to earlier death 6, reaching 
disease milestones earlier 7 and earlier onset of secondary progressive MS 8,9. While the 
negative impact of smoking in MS is well established, there is less evidence whether smoking 
cessation is beneficial. Retrospective analyses have shown that smoking cessation may reduce 
the risk of reaching disability milestones 9, and quitting earlier is associated with stronger 
reductions in risk 5. These milestones, however, are confounded by other factors such as mood 
10
Studying the effects of exposures known to be harmful, such as smoking, poses specific 
challenges. One approach is to use registry data where the self-directed choice of each study 
subject determines their exposure. Registry studies are subject to several biases, in particular 
those associated with geographical and temporal variations in data-collection 11. Some cross-
site and longitudinal stability can be introduced by the use of patient reported outcomes (PROs) 
in which participants answer questions about certain aspects of their own health. PROs are not 
widely used as standardised clinical outcome measures in MS and preference has been for tools 
such as the Expanded Disability Status Scale (EDSS). However, PROs have been shown to be 
the better predictor of outcome when integrated into a patient-specific, personalised approach 
12. Two validated PROs have established use in assessing the motor impact of MS: the MS 
walking scale 12 (MSWS-12) 13, and the motor component of the MS impact scale 29 (MSIS-
29-Phys) 14. Clinically relevant changes, corresponding to established EDSS outcomes, have 
been validated both for the MSWS-12 15 and the MSIS-29 16,17. The MSIS-29 has also been 
correlated with mortality18. 
The United Kingdom MS Register (UKMSR) is a primarily patient-driven registry of PRO 
based data that has been active since 2011. We have used UKMSR data from almost 8000 
participants to conduct a PRO-based study investigating the effects of smoking, and of smoking 
cessation, in pwMS. To our knowledge, this represents the largest investigation into the effects 
of smoking cessation in MS and the largest study of smoking in any neurological disease to 
use PROs. We have used MSWS-12, MSIS-29-Phys and hospital anxiety and depression scales 
(HADS) 19. Firstly, we utilised historical data on smoking and smoking cessation to assess 
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current impact on functional status. We then used prospectively collected data in the same 
cohort yearly over 4 years to measure average change in the PROs. Finally, we modelled the 
PRO results for use in time to event analyses using confirmed clinically relevant worsening 




The UKMSR is an online, UK-wide register supported by National Health Service (NHS) 
clinical centres (REC: South West Central Bristol NRES 16/SW/0194). The register includes 
independent verification of treatments and EDSS outcomes from NHS centres in a separate but 
overlapping population. Participants enter data regularly (3 monthly from 2011 to 2018 and 6 
monthly subsequently) and are sent reminders by email. Since September 2018 participants 
have a 28-day window in which to complete the PROs, although often they are all completed 
in one day. For this study demographics and disease specific data were assessed at the first 
questionnaire (baseline) or within 12 months prior or 6 months after completion of the first 
questionnaire. Demographic data collected included age, gender, ethnicity (Black Asian or 
minority ethnic group (BAME)/not). Disease-specific data was also obtained, including disease 
length (in years, from initial symptoms), disease type at diagnosis (secondary and primary 
progressive/not progressive) and whether the participant was on a disease modifying treatment 
(DMT) or not for their MS (highly active/normally active/none). Highly active treatments were 
defined as: alemtuzumab, cladribine, daclizumab, fingolimod, mitoxantrone, natalizumab, 
crelizumab, ofatumumab, and rituximab. A univariate statistical analysis was completed on 
these data; Chi-squared test for categorical, one way ANOVA tests for comparison of 
parametric means and Kruskal-Wallis tests for non-parametric data.
PRO Questionnaires
Three PROs were used: MSIS-29-Phys, MSWS-12 and the HADS scale. The MSIS-29-Phys 
subscore version 1 (MSIS-29v114) was used prior to April 2012, and version 2 (MSIS-29v220) 
was used subsequently. Answers to the 20 questions that form the MSIS-29 Phys sub-score are 
each scored between 1 and 5 in version 1, and between 1 and 4 in version 2. These scores give 
a total ranging from 20 to 100 for MSIS-29v1, and of 20 to 80 for MSIS-29v2. In order to 
account for the changes in scales, totals were rescaled to a value in the range of 0 to 100 using 
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a unity-based normalisation procedure 21. A 10-point increase in the normalised score 
corresponds to an 8-point increase in the MSIS-29v1 physical score. This change reflects 
clinically relevant worsening 16,17. MSWS-12 version 2 13 was used to assess walking function.  
Participants were only excluded from the MSWS-12 assessment if they indicated that they 
could not walk. The score was normalised as above.  A 10-point change in the normalised score 
corresponds to a 5.4-point change in the raw score which reflects a clinically relevant change 
15. The HADS provides scores for anxiety and depression 19 A 2-point change in either of these 
sub-scores corresponds to a clinically relevant change 22.
Retrospective and prospective cohort study design
The retrospective analysis was conducted using the population in whom valid data was 
available for date of birth, gender, and smoking status. Participants needed to have answered 
at least one of the three PROs and the first questionnaire answered for each PRO was used.
Two approaches were taken for the prospective cohort analysis. In the first, for the 4-year 
prospective parallel group analysis, participants were identified who had completed each of the 
3 PROs at baseline and every year (±60 days) over a 4-year period. Secondly, for the time to 
event analyses ‘streaks’ of longitudinal data were obtained from participants who fulfilled 
specific criteria. To be included in a streak, participants had to have completed at least three 
sets of PRO questionnaires. The minimum time interval between each questionnaire was 15 
days and the maximum interval could not be longer than 240 days. The longest sequence of 
questionnaires completed by each participant defined by these criteria was selected for each 
participant. In the event that a participant had more than one longest streak (of equal length), 
then the most recent was chosen. A separate set of streaks was built for each questionnaire. 
Clinically significant step changes were used as ‘events’ for time to event analysis. Information 
about the time to event was provided from timestamps which were automatically appended by 
the database tables. Censoring occurred at the date when the PRO score increased by a 
clinically significant step or, alternatively, when the last questionnaire of the streak was 
completed. The maximum number of PROs answered was used as a confounding variable in 
the time to event analysis.
Smoking status
Questions about smoking status were available to answer at any time and were reviewable at 
the time of every email reminder when the regular battery of PROs were completed. 
Participants were asked if they had ever smoked and, if they answered yes, whether they 
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continued to smoke. This provided three distinct categories: never, former, and current smoker. 
If the participant answered that they had stopped smoking, then the cessation date was 
requested. The number of cigarettes smoked per day in current and former smokers was also 
requested. This was classified as light (≤7), moderate (7-12) and heavy (≥13) based on the 
distribution of the data. Pack years smoked is defined by the rate of daily smoking in percentage 
of standard 20 cigarette packs multiplied by the total time smoked in days. 
Statistical analysis
All statistical analysis was performed using the R statistical programming language, version 
3.5.1, in the RStudio environment, version 1.1.463. Boxplots were used to illustrate the 
retrospective analysis (minimum score, lower quartile, median, upper quartile, maximum 
score). Generalised linear modelling was used for the retrospective analysis and Cox regression 
modelling was used to analyse the effects of being a never-, current- and former smoker on the 
rate of clinically significant events using the ‘survival’ package (v2.43-3) in R (v3.5.3). 
Baseline variables considered were age at first assessment, disease length, MS type at diagnosis 
(progressive as reference vs not progressive), gender (female as reference), ethnicity group 
(BAME vs white) and pack years smoked. DMT, either highly active, normally active or none, 
was modelled as a time varying covariate. Linear mixed models for repeated measures were 
used to analysis the prospective parallel groups using the ‘lme4’ package (v1.1-7) optimised 
using restricted maximum likelihood estimates. Dependent variables were the normalised 
MSIS-29 Phys, MSWS-12, HADS anxiety and depression scores. Fixed effects for time, 
smoking status, age, gender, time since onset, treatment type, pack years, and ethnicity were 
added, as well as the interaction terms between time and smoking status. The study participants 
were included as a random effect. Estimates of the fixed effects and their 95% confidence 
intervals are reported. 
Data availability




Seven thousand nine hundred and eighty-three pwMS who had a valid smoking status and had 
completed at least one PRO were identified from the UKMSR database (n=16187; valid date 
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of birth and gender). Details of the excluded population is provided in supplementary Table 1. 
Four thousand six hundred and forty-two pwMS in turn had the required information to produce 
a streak of prospective time to event data. For the 4-year prospective parallel cohort analysis 
923 pwMS were available given the selection criteria (Table 1). Using simultaneously collected 
data (N=4591) we confirmed that the MSIS-29-Phys was highly correlated with the MSWS-
12 (r=0.87, 95%CI [0.86, 0.87]). MSIS-29 was less so with the HADS-depression (r=0.61, 
95%CI [0.59, 0.63]) and HADS-anxiety (r=0.37, 95%CI [0.35, 0.40]). The correlation of the 
MSWS-12 to the HADS-depression was higher (r=0.50, 95%CI [0.48, 0.53]) than the MSWS-
12 correlation with the HADS-anxiety (r=0.21, 95%CI [0.18, 0.23]). HADS-depression and 
HADS-anxiety was also correlated with each other (r=0.60, 95%CI [0.59, 0.62]). 
Smoking prevalence in the UKMSR population
Smoking status was independently verified in our data provided by NHS clinical centres. There 
were 858 pwMS who had smoking data on both the portal submitted by pwMS and in records 
collected by their clinical team. Of these, 265 records were independently collected within two 
months of each other since 2015. In the clinical data 11.0% were current smokers versus 14.7% 
for the online portal (p = 0.0491); 10 pwMS had told their healthcare team they do not smoke 
but revealed they did smoke on the portal. 
4130/7983 (51.7%) of the total MS population were ever smokers; 1315/7983 (16.5%) were 
current smokers which is similar to the 10-year average prevalence across the entire UK from 
2011 (16.68%, p = 0.619)23 2815/4130 (68.2%) of the smokers had stopped at the time of data 
collection; this proportion is higher than for the total UK population between 2011 and 2019, 
(57.2%, p = <0.001). In the time to event population, 675/4642 (14.5%) were current smokers 
and 130/923 (13.7%) of the 4-year prospective population were current smokers. As the 
populations studied became more selective and required longer follow-up (total > time to event 
> 4-year parallel group) age and disease length increased as did the proportion of pwMS with 
progressive diagnoses but also the proportion of males (Table 1). 
Retrospective analysis of smoking impact
The total population was used for the retrospective analysis (n=7983; Table 1). For all PROs, 
those who were current smokers at the time of completing their first questionnaire had higher 
disability, depression and anxiety compared to those who had never smoked (Figure 1A). 
Smoking cessation was associated with a range of PRO scores depending on the PRO. HADS-
Page 10 of 30








ab385/6384574 by guest on 20 O
ctober 2021
depression scores were similar in former smokers compared to never smokers (Fig1A-panel 4). 
MSIS-29-Phys and HADS-anxiety scores were lower in former smokers than those of current 
smokers but higher than those of never smokers (Fig1A-panels 1 and 3). There was no change 
in the MSWS-12 scores compared to current smokers (Fig1A-panel 2). In those who were still 
smoking, heavier smoking burden (light, moderate, heavy) was associated with a higher PRO 
score in all cases (Figure 1B). In those who were former smokers, the effects of increased 
smoking burden were still evident except for in the HADS-anxiety score (Figure 1C). PRO 
score was not correlated with time since quitting in former smokers in all PROs; MSIS-29-
Phys (r=0.04, 95%CI [0.003, 0.078], n=2754), MSWS-12 (0.11, 95%CI [0.07, 0.15], n=2581), 
HADS anxiety Score (-0.19, 95%CI [-0.22, -0.15], n=2779) and HADS depression score (-
0.08, 95%CI [-0.11, -0.04], n=2779).
Carrying out a multi variable linear regression adjusting for age at baseline, time since onset, 
MS type at diagnosis, ethnicity and whether the subject was receiving a DMT (Table 2) 
confirmed the expected impact of age and disease length and having progressive disease on 
PRO scores but also demonstrated benefits of being on a DMT and being non-white. The 
analysis confirmed that smokers had higher PROs scores than never smokers with a mean 
increase in 4.7 and 3.7 points for the MSIS-29-Phys and MSWS-12 respectively and 0.79 and 
0.74 for the HADS-anxiety and depression respectively. There was no significant difference 
between former smokers and never smokers in any of the PROs. However, for each additional 
pack year of smoking there was a significant increase in all PROs: 0.19 point for the MSIS-29-
Phys, 0.21 point for the MSWS-12 and 0.03 points for both HADS scores indicating a 
cumulative effect of smoking on disability. 
Prospective parallel group analysis of smoking impact over 4 years 
To determine the impact of smoking on PROs over the longer term we utilised a subgroup of 
pwMS (n=923; Table 1) who had completed the PROs every year over 4 years. Average scores 
were plotted for each category of smoking status (Figure 2). The MSIS-29-phy, MSWS-12 and 
HADS-depression score worsened over time whereas the HADS anxiety remained stable. 
Smoking status was significant controlling for time across all PROs. Linear mixed modelling 
demonstrated that at year 4 MSIS-29-Phys (5.03, [3.71, 6.34]), MSWS-12 (5.28, [3.62, 6.94]), 
and HADS-Depression (0.71, [0.47, 0.96]) scores increased whereas the HADS-Anxiety did 
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not change. Being a current smoker was associated with a higher score than never smokers for 
MSIS-29-Phys 3.05 [0.22, 5.88] and HADS-Anxiety 1.14 [0.52,1.76], whereas former smokers 
had a lower score at year 4 by -2.91[-5.03, -0.79] MSIS-29-Phys points. Average scores for 
MSIS-29, MSWS-12 and HADS depression increased steadily for each year after baseline 
when accounting for both fixed and random effects (see supplementary Table 2 for full results). 
Time to event analyses
The prospective time to event analysis was performed using streaks of data created using the 
criteria described above. Streak length ranged from 180 days to 8 years. Median streak length 
(in years) for MSIS-29-Phys was 3.22 (interquartile range (IQR) 3.65), MSWS 2.82 (IQR 3.65) 
and HADS 3.19 (IQR 3.63). Median time (in days) between each questionnaire in the streak 
was 115 (IQR 77) for the MSIS-29-Phys, 111 (IQR 65) for the MSWS and 114 (IQR 74) for 
the HADS. 
Cumulative event probabilities for time to worsening event were calculated for each PRO 
(Figures 3 and 4). Cox regression models were created for time to worsening, controlling for 
age at baseline, gender, baseline score, MS type at diagnosis with DMT treatment as a time-
varying covariate (Table 3). Together, these demonstrated that current smoking was associated 
with a shorter time to worsening of MSIS-29-Phys (Table 3, Figure 3A), MSWS-12 (Table 3, 
Figure 3B), HADS-anxiety events (Table 3, Figure 4A) and HADS-depression (Table 3, Figure 
4B). There was no significant difference in the rate of events between never and former 
smokers.
The relationship between anxiety, depression and motor events. 
The HADS-anxiety and HADS-depression PROs were separately modelled against each motor 
PRO (Table 4). 1860 participants shared time to event data starting at the same time for all 
PROs. Using Cox modelling controlling for baseline MSIS-29-Phys (Table 4, column 1) and 
MSWS-12 (Table 4, column 2) score, age, gender, MS Type at diagnosis, ethnicity and DMT 
as a time-varying covariate, current smoking was associated with an increased risk of having a 
higher MSIS-29-Phys and MSWS-12 score independently of the baseline HADS-anxiety and 
HADS-depression score. An increasing baseline HADS-depression score was independently 
associated with a worsening of both the MSIS-29-Phys and MSWS-12.  Next, we used Cox 
models to investigate the impact of the MSIS-29-motor on the HADS-anxiety (Table 4, column 
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3) and HADS-depression scores (Table 4, column 4). In both cases, being a current smoker 
was associated with a higher MSIS-29-Phys score and HADS-anxiety score controlling for age, 
gender, MS Type at diagnosis, ethnicity and DMT as a time-varying covariate. 
Discussion
The UK MS Register has enabled the identification of a UK wide, community-based registry 
population of almost 8000 people to demonstrate the benefits of smoking cessation in MS. 
Smoking is associated with a dose related worsening of motor function and smokers 
experience an accelerated rate of worsening compared to non-smokers. Once accrued, the 
damage does not resolve when smoking is stopped. Importantly however, we have shown 
that, following smoking cessation, there is a deceleration in the rate of motor deterioration so 
that it matches the rate of motor decline in those who have never smoked.
The use of registry data has allowed us to overcome some of the challenges associated with 
studying harmful interventions. The use of PROs has, in turn, negated some of the limitations 
which are associated with registry data. One drawback of registry data is the potential 
variability associated with data drawn from multiple sites and multiple operators. This 
variability is particularly true of the EDSS, a quantifiable neurological examination and the 
most commonly used outcome in MS 24. The use of validated PROs has allowed a more 
uniform UK-wide approach to data collection. It is especially reassuring that the retrospective 
analysis highlights the known benefits of DMTs in MS as this has previously been shown 
with other registries using the EDSS 25. Interestingly we found that non-white ethnicity is 
associated with lower PRO scores. Generally non-white populations have similar disability to 
white populations. However socioeconomic factors including participation, health literacy 
and health behaviours differ in non-white populations. As our population is a volunteer 
population therefore this non-white population could be biased towards those with a better 
outcome. 26 Furthermore, we have reinforced the appropriateness of PROs in this setting by 
using a prospective parallel group analysis to show that PROs related to motor disability 
worsen over 4 years irrespective of smoking status, as has been previously documented with 
the EDSS.  
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We have extended the use of PROs by adapting them for use in time to event analyses. Such 
analyses are common in MS trials 27. Regular data capture has allowed us to identify a 
population in whom smoking status can be confirmed at each data timepoint and in whom 
clinically significant PRO step changes can be identified and timestamped over a period of up 
to 8 years. PROs tied to clinically relevant outcomes in this way offer the opportunity to 
determine the interaction with key potential confounders such as depression and anxiety. 
Here, we have shown that, uniquely among the tested PROs, anxiety does not worsen over 
time, even though anxiety is higher in current smokers, improves with smoking cessation and 
is independently associated with the motor score. This implies that anxiety it is not directly 
linked to MS. Depression on the other hand, does appear to be linked with the disease itself, 
worsening over time and, notably, deteriorating more rapidly in former smokers compared to 
never smokers. There is a potential that depression could drive both continued smoking and 
lack of exercise.
There are several limitations of our study. The UKMSR is predominantly a self-declared 
register but here we have confirmed smoking status against independent healthcare team 
verification. Interestingly, we find that the rate of smoking declaration is higher in the self-
reported data than in the clinical documentation. This discrepancy raises questions about how 
clinical teams can target smoking cessation advice if they are not aware of a patient’s true 
smoking status. A further major issue with registries is that selection bias can be augmented 
when participants are effectively allocating themselves into study groups. Therefore, we 
cannot exclude the indirect effects of other beneficial health related activity that may go hand 
in hand with smoking cessation. The UKMSR is representative of the UK MS population 11 
but here, by using a subset of the total study population, we find that completing more PROs 
and with greater regularity is associated with lower rates of smoking. Participants who have 
completed more PROs also tend to be older, male, and to have more progressive MS. Despite 
these apparent biases, we are still able to demonstrate the impact of smoking cessation in all 
populations.
Despite longstanding knowledge that smoking is associated with a poor outcome in MS, we 
show that the rate of smoking in pwMS is on par with the national rates. The number of 
former smokers is higher than the national average indicating the rates of smoking may have 
previously been higher still in pwMS in common with prior populations studied 7,9. This 
suggests that pwMS may not be receiving sufficient encouragement and support to stop 
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smoking. This failure is in common with a number of other conditions in which smoking is 
known to have a negative impact. Recognition of such a failure has led to calls for advice 
about smoking cessation to be included in standard clinical guidelines for relevant diseases 28 
and adds to the arguments for generating evidence for the effectiveness of smoking cessation 
interventions 29. Here we have provided further impetus for pwMS to stop smoking by 
showing that the rate of motor deterioration is not only accelerated in smokers, but that it 
returns to the rate of deterioration in non-smokers following smoking cessation.
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Figure legends
Figure 1. Boxplots demonstrating the effect of smoking cessation (A) and smoking amount 
(light, moderate, heavy) in current (B) and former smokers (C) for the MSIS-29-phy (panel 1), 
MSWS-12 (panel 2), HADS-anxiety (panel 3) and HADS-depression (panel 4).
Figure 2. Parallel group analysis of mean change (±standard error) for former (grey line), 
current (black dashes) and never (light grey dots) smokers. Plots are over 4 years for MSIS-29-
Phys (A: n=731:382 never-smokers, 105 current-smokers and 244 former smokers), MSWS-
12 (B: n=573: 317 never-smokers, 81 current-smokers and 175 former smokers), HADS-
anxiety (C) and HADS-depression (D: n=766: 407 never-smokers, 107 current-smokers and 
252 former smokers). 
Figure 3. Cumulative event (1-Kaplan-Meier) curves for MSIS-29-phy (A: n=4436) and 
MSWS-12 (B: n=3902). Being a current smoker (dots) was associated with a higher rate of 
worsening events in both MSIS-29-Phys (Wald test chi-square, [df=2] =13.32, p=0.0013; 
median time [95%CI]: 673 days [600, 787]) and MSWS-12 (Wald test chi-square, [df=2] 
=10.16, p=0.0061; median time 936 days [803, 1135]) compared to never (line; MSIS-phys 
median time 883 days [819, 960]; MSWS-12 median time 1131 [1035, 1317]) and former 
smokers (dashes; MSIS-phys median time 829 days [772, 930]; MSWS-12 median time 1250 
[1029, 14567]).
Figure 4. Cumulative event (1-Kaplan-Meier) curves for HADS-anxiety (A: n=4511) and 
HADS-depression (B: n=4511). Being a current smoker (dots) was associated with a higher 
rate of both HADS-anxiety (Wald test chi-square, [df=2] =12.68, p=0.0017; median time 907 
days [742, 1239]) and -depression (Wald test chi-square, [df=2] =54.25, p<0.0001; median 
time 760 days [629, 934]). PRO worsening events compared to never (line; HADS-anxiety 
median time 1318 days [1168, 1519]; HADS-depression median time 1392 [1207, 1563]) and 
former smokers (dashes; HADS-anxiety median time 1318 days [1118, 1483]; HADS-
depression median time 1110 [1034, 1270]).
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Table 1 Demographics and PRO outcomes of the total population with a given smoking status (n=7983), the time-to-event (n=4642) and parallel group (n=923) population









n below (n = 3853) (n = 2378) (n = 487) (n = 2815) (n = 1589) (n = 309) (n = 1315) (n = 675) (n = 127)
Age at Baseline, 
mean (SD)
7983 4642 923 48 (11.5) 49.6 (11) 51.5 (10) 50.7 (11.2) 52.6 (10.7) 54.7 (9.8) 45.3 (11.1) 47.3 (10.9) 49.1 (10.6)
Time Since MS 
Onset, mean 
(SD)
7826 4596 919 13.3 (10.6) 14.3 (10.8) 16.1 (10.7) 15.6 (11.8) 16.5 (12) 17.5 (11.4) 11.9 (9.8) 13 (10.2) 14.2 (10.5)
Gender: female, 
N (%)
7983 4642 923 3016 (78.3) 1856 (78) 375 (77) 1934 (68.7) 1070 (67.3) 185 (59.9) 940 (71.5) 457 (67.7) 84 (66.1)








7983 4642 923 1167 (30.3) 810 (34.1) 171 (35.1) 656 (23.3) 407 (25.6) 73 (23.6) 359 (27.3) 209 (31) 41 (32.3)
On Highly Active 
DMT N(%)
7983 4642 923 59 (1.5) 38 (1.6) 6 (1.2) 38 (1.3) 21 (1.3) 2 (0.6) 25 (1.9) 13 (1.9) 4 (3.1)
Black, Asian and 
minority ethnic, 
N (%)
7534 4408 868 271 (7) 137 (5.8) 17 (3.5) 177 (6.3) 75 (4.7) 7 (2.3) 118 (9) 57 (8.4) 9 (7.1)
MSIS-29-Phys, 
median [IQR]
7840 4436 922 36.7 [16.7–60] 36.7 [18.3–
58.6]
40.6 [21.7–61.7] 43.3 [23.3–
64.4]
45 [25–65] 48.3 [28.3–66.7] 48.3 [26.7–69.1] 50 [30–70] 48.8 [30–65.6]
MSWS-12, 
median [IQR]
7318 3902 885 47.6 [14.3–78.6] 50 [16.7–78.6] 61.9 [26.2–85.7] 59.5 [23.8–
85.7]
59.5 [26.2–85.7] 71.4 [40.5–90.5] 59.5 [28.6–85.7] 64.3 [31–85.7] 66.7 [39.3–86.9]
HADS Anxiety, 
median [IQR]




7923 4511 923 6 [3–9] 6 [3–9] 5 [3–8.5] 6 [4–9] 6 [4–10] 6 [4–9] 8 [5–11] 7 [5–10] 7 [4–10]
SD – standard deviation; IQR –interquartile range.
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Table 2 Multivariable linear regression of retrospective data (MSIS-29-Phys n=7840, MSWS-12 n= 7318, HADS n = 7923)
MSIS-29-Phys MSWS-12
 Estimate, 95% CI p-value Estimate, 95% CI p-value
(Intercept)  31.45, [28.45, 34.44] <0.0001 26.25, [22.36, 30.13] <0.0001
Former −0.21, [−2.12, 1.7] 0.83 −0.63, [−3.11, 1.84] 0.62Smoking status (ref: Never)
Current 4.65, [1.87, 7.42] 0.001 3.68, [0.09, 7.28] 0.044
Age  0, [−0.07, 0.07] 0.97 0.24, [0.15, 0.32] <0.0001
Gender (ref: Female) Male −0.86, [−2.12, 0.39] 0.18 1.04, [−0.6, 2.68] 0.21
Time since onset  0.54, [0.48, 0.59] <0.0001 0.7, [0.62, 0.78] <0.0001
Progressive (ref: No) Yes 12.67, [11.14, 14.2] <0.0001 20.9, [18.87, 22.93] <0.0001
Treatment (Ref: No Treatment) Normally Active −5.41, [−6.71, −4.12] <0.0001 −6.37, [−8.02, −4.72] <0.0001
Highly Active −6.63, [−11.06, −2.2] 0.0034 −6.37, [−11.9, −0.85] 0.024
Black, Asian, Minority Ethnic (ref: No) Yes −3.71, [−5.83, −1.59] 0.00059 −5.54, [−8.29, −2.79] <0.0001
Pack Years 0.19, [0.11, 0.26] <0.0001 0.21, [0.11, 0.31] <0.0001
HADS-Anxiety HADS-Depression
(Intercept) 11.79, [11.27, 12.3] <0.0001 6.7, [6.21, 7.2] <0.0001
Former 0.15, [−0.18, 0.47] 0.38 −0.13, [−0.45, 0.18] 0.41Smoking status (ref: Never)
Current 0.79, [0.31, 1.26] 0.0012 0.74, [0.28, 1.2] 0.0015
Age  −0.09, [−0.1, −0.07] <0.0001 −0.02, [−0.03, −0.01] 0.00016
Gender (ref: Female) Male −0.84, [−1.05, −0.62] <0.0001 0.06, [−0.14, 0.27] 0.56
Time since onset  0.02, [0.01, 0.03] 0.0031 0.03, [0.02, 0.04] <0.0001
Progressive (ref: No) Yes 0.14, [−0.12, 0.4] 0.29 0.81, [0.56, 1.06] <0.0001
Treatment (Ref: No Treatment) Normally Active −0.3, [−0.52, −0.08] 0.0081 −0.52, [−0.74, −0.31] <0.0001
Highly Active −1.52, [−2.27, −0.76] <0.0001 −1.25, [−1.98, −0.52] 0.00075
Black, Asian, Minority Ethnic (ref: No) Yes −0.18, [−0.54, 0.18] 0.32 −0.24, [−0.59, 0.11] 0.18
Pack Years  0.03, [0.01, 0.04] <0.0001 0.03, [0.02, 0.05] <0.0001
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Table 3 Cox regression models for the time to worsening of the PROs (hazard ratios and 95% confidence intervals)
Hazard ratio,95% CI MSIS-29-Phys MSWS-12 HADS-Anxiety HADS-Depression
Former 1.02, [0.88, 1.17] 0.97, [0.84, 1.13] 1.02, [0.88, 1.17] 1.01, [0.88, 1.17]Smoking status (ref: 
Never) Still 1.3, [1.04, 1.62] 1.16, [0.92, 1.47] 1.25, [1, 1.57] 1.25, [1, 1.56]
PRO baseline score 0.99, [0.99, 1] 1, [1, 1.01] 1, [0.99, 1.01] 1, [0.99, 1.01]
Max number of PROs 1, [0.99, 1.01] 1, [0.99, 1.01] 1, [0.99, 1] 1, [0.99, 1.01]
Age at baseline 
(Years)
1, [1, 1.01] 1, [0.99, 1] 1, [1, 1.01] 1, [1, 1.01]
Gender (ref: Female) Male 0.97, [0.88, 1.06] 0.96, [0.87, 1.06] 0.98, [0.89, 1.07] 0.98, [0.89, 1.07]
Time Since Onset 
(Years)
1, [1, 1.01] 1, [0.99, 1] 1, [0.99, 1] 1, [0.99, 1]
Progressive (ref: No) Yes 1.22, [1.09, 1.36] 1.05, [0.94, 1.18] 1.11, [1, 1.24] 1.11, [1, 1.24]
Normally 
Active




1.11, [0.77, 1.62] 1.1, [0.76, 1.6] 1.13, [0.77, 1.64] 1.13, [0.78, 1.65]
Black, Asian, Minority 
Ethnic (ref: No)
Yes 0.86, [0.72, 1.04] 0.85, [0.7, 1.04] 0.88, [0.73, 1.06] 0.88, [0.74, 1.06]
Pack Years 1, [1, 1.01] 1, [0.99, 1.01] 1, [0.99, 1.01] 1, [0.99, 1.01]
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Table 4 Cox regression models for the time to worsening of the PROs incorporating anxiety and depression (hazard ratios 
and 95% confidence intervals)
Hazard ratio,95% 
CI
MSIS-29-Phys MSWS-12 HADS-Anxiety HADS-Depression
Former 1.02, [0.88, 1.18] 0.98, [0.84, 1.14] 1, [0.86, 1.16] 0.99, [0.85, 1.15]Smoking status 
(ref: Never) Still 1.28, [1.02, 1.6] 1.16, [0.92, 1.47] 1.27, [1.01, 1.6] 1.22, [0.97, 1.55]
MSIS-29-Phys 0.99, [0.99, 0.99] 0.97, [0.96, 0.97] 0.96, [0.96, 0.97]
MSWS-12 1, [1, 1.01] 1.03, [1.02, 1.03] 1.03, [1.02, 1.03]
HADS-Anxiety 0.99, [0.98, 1.01] 0.99, [0.98, 1.01] 1.04, [1.02, 1.05]
HADS-Depression 1.05, [1.03, 1.06] 0.99, [0.98, 1.01] 1.05, [1.04, 1.07]
Max MSIS-29 1.02, [0.97, 1.07] 1.02, [0.97, 1.07] 1.01, [0.96, 1.07]
Max MSWS-12 1.03, [1, 1.05] 1.01, [0.99, 1.03] 1.01, [0.99, 1.03]
Max HADS 0.98, [0.94, 1.03] 0.97, [0.96, 0.99] 0.97, [0.93, 1.03] 0.98, [0.93, 1.03]
Age at baseline 1, [1, 1.01] 1, [0.99, 1] 1, [0.99, 1] 1, [0.99, 1]
Gender (ref: 
Female)
Male 0.94, [0.86, 1.04] 0.96, [0.87, 1.05] 0.94, [0.86, 1.04] 0.9, [0.82, 0.99]
Time since onset 1, [1, 1.01] 1, [0.99, 1] 1, [0.99, 1] 1, [0.99, 1]
Progressive (ref: 
No)
Yes 1.24, [1.12, 1.39] 1.06, [0.94, 1.19] 1.01, [0.89, 1.13] 1.02, [0.91, 1.15]
Normally Active 0.99, [0.9, 1.09] 1.05, [0.95, 1.16] 1.03, [0.93, 1.14] 1.02, [0.93, 1.13]Treatment (Ref: No 




Yes 0.86, [0.72, 1.03] 0.85, [0.7, 1.04] 0.87, [0.71, 1.05] 0.87, [0.72, 1.06]
Pack Years 1, [1, 1.01] 1, [1, 1.01] 1, [1, 1.01] 1, [1, 1.01]
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